Get Knowledge And Acceptance Of The Hpv Vaccine Among Emory S Undergraduate Student Population - Etd

By Race/Ethnicity Detailed Trend GraphsMost Recent Estimates (2022) Percent vaccinated95% Confidence Interval Non-Hispanic White 55.8 53.4 - 58.1 Non-Hispanic Black 61.4 56.4 - 66.3 Hispanic 61.3 56.6 - 65.82 more rows

More than 98% of recipients develop an antibody response to HPV types included in the respective vaccines 1 month after completing a full vaccination series. However, there is no known serologic correlate of immunity and no known minimum titer determined to be protective.

HPV vaccine coverage in England for females completing a 2-dose HPV schedule by year 9 (born 1 September 2008 to 31 August 2009) was 62.9%. This is 4.4 percentage points lower than the 67.3% achieved in 2021 to 2022 and 21% lower than pre-pandemic (2018 to 2019).

More than 90 percent of sexually active men and 80 percent of sexually active women will be infected with HPV in their lifetime. Around 50 percent of HPV infections involve certain high-risk types of HPV, which can cause cancer. Most of the time, the body clears these infections and they do not lead to cancer.

The HPV vaccine acceptance rates varied widely across the 86 studies (12.0 to 97.5%). Among these, 19 studies reported high acceptance rates (≥ 80%), 62 studies showed moderate acceptance rates (> 30% to < 80%), and five studies reported low acceptance rates (≤ 30%).

The vaccine is very, very effective. If you are vaccinated before being exposed to the virus, the HPV vaccine is 97 percent effective in preventing cervical cancer and cell changes that could lead to cancer. Plus, it's almost 100 percent effective in preventing external genital warts.

Conclusions. Even though the overall acceptance rate of the HPV vaccine is around 60%, participants' knowledge of cervical cancer, HPV, and the HPV vaccine was low, with an average of less than 50%.